Bio-Techne Corp (TECH)
| Market Cap | 13.77B |
| Revenue (ttm) | 759.65M |
| Net Income (ttm) | 248.29M |
| Shares Out | 38.54M |
| EPS (ttm) | 6.26 |
| PE Ratio | 56.93 |
| Forward PE | 67.57 |
| Dividend | $1.28 |
| Dividend Yield | 0.36% |
| Trading Day | January 22 |
| Last Price | $356.59 |
| Previous Close | $355.68 |
| Change ($) | 0.91 |
| Change (%) | 0.26% |
| Day's Open | 356.13 |
| Day's Range | 353.28 - 358.26 |
| Day's Volume | 114,088 |
| 52-Week Range | 160.61 - 358.26 |
MINNEAPOLIS, Dec. 2, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics (NASDAQ: RGLS) announced a collaboration to support Regulus with biomarker analysis for...
MINNEAPOLIS, Nov. 11, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Stephens Annual ...
Bio-Techne Corporation (TECH) CEO Chuck Kummeth on Q1 2021 Results - Earnings Call Transcript
Techne (TECH) delivered earnings and revenue surprises of 25.44% and 9.96%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
MINNEAPOLIS, Nov. 5, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the first quarter ended September 30, 2020. First Quarter FY2021 Snapsho...
MINNEAPOLIS, Nov. 5, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended Sep...
MINNEAPOLIS, Nov. 4, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Stifel 2020 Virtu...
Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, Oct. 26, 2020 /PRNewswire/ -- Kantaro Biosciences, LLC (Kantaro), a joint venture between the Mount Sinai Health System and RenalytixAI (LSE:RENX / NASDAQ: RNLX), and partner Bio-Tec...
MINNEAPOLIS, Oct. 19, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that ProteinSimple, a Bio-Techne brand, released its SARS-CoV-2 Multi-Antigen Serology Module f...
MINNEAPOLIS, Oct. 1, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the opening of its new Canadian office located in Toronto. This new office will be the workplace ...
MINNEAPOLIS, Sept. 30, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the grand opening of its approximately 61,000 square foot state-of-the-art GMP (Good Manufactu...
MINNEAPOLIS, Sept. 22, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the expansion of the Advanced Cell Diagnostics (ACD)-branded RNAscope™ technology with release ...
MINNEAPOLIS, Sept. 21, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that the B-MoGen Biotechnologies portfolio of genome engineering services, GMP therapeutic man...
MINNEAPOLIS, Sept. 17, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and QIAGEN N.V.
These are the biotech stocks with the best value, fastest growth, and most momentum for Q4 2020.
MINNEAPOLIS, Aug. 11, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the release of the SARS-CoV-1/2 Spike RBD LlaMABody Recombinant Antibody, which binds to the SAR...
Bio-Techne's (TECH) CEO Chuck Kummeth on Q4 2020 Results - Earnings Call Transcript
Shares of Bio-Techne (NASDAQ:TECH) were unchanged after the company reported Q4 results.
MINNEAPOLIS, Aug. 4, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the fourth quarter ended June 30, 2020.
MINNEAPOLIS, Aug. 3, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the appointment of Julie L.
Bio-Techne And Kantaro Biosciences To Launch A Quantitative Research Use Only COVID-19 Serology Test
MINNEAPOLIS and NEW YORK, Aug. 3, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences ...
Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bio-Techne (TECH) is expected to report earnings on Aug. 4. The stock is now trading 1% below the 282.62 buy point from a second-stage cup without handle that it cleared earlier.
MINNEAPOLIS, July 21, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has completed validation testing for COVID-19 caus...
MINNEAPOLIS, July 20, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the expansion of the RNAscope™ platform with the release of the miRNAscope™ Assay. The RNAscope ...
Techne (TECH) could produce exceptional returns because of its solid growth attributes.
MINNEAPOLIS, June 11, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has established a new partnership with ZERO – The ...
MINNEAPOLIS, June 8, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the release of GMP ProDots™ Proteins to support cell and gene therapy manufacturing workflows. GM...
MINNEAPOLIS, May 27, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the virtual Jefferies ...
MINNEAPOLIS and NEW YORK, May 19, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences ...
Bio-Techne Corporation (TECH) CEO Chuck Kummeth on Q3 2020 Results - Earnings Call Transcript
Techne (TECH) delivered earnings and revenue surprises of 23.01% and 5.31%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech and drug manufacturing companies with the strength to weather further coronavirus storms.
Bio-Techne Corporation (TECH) CEO Chuck Kummeth on Q2 2020 Results - Earnings Call Transcript
Techne (TECH) delivered earnings and revenue surprises of -5.26% and -3.50%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
CELG vs. TECH: Which Stock Is the Better Value Option?
Bio-Techne Corporation (TECH) CEO Chuck Kummeth on Q1 2020 Results - Earnings Call Transcript
Techne (TECH) delivered earnings and revenue surprises of -0.93% and 1.77%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Bio-Techne Corporation (TECH) CEO Chuck Kummeth on Q4 2019 Results - Earnings Call Transcript
Techne (TECH) delivered earnings and revenue surprises of -4.58% and -3.20%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
CBM vs. TECH: Which Stock Is the Better Value Option?
CEO of Bio-techne Corp (NASDAQ:TECH) Charles R. Kummeth (insider trades) sold 16,969 shares of TECH on 07/10/2019 at an average price of $213.12 a share.
CEO of Bio-techne Corp (NASDAQ:TECH) Charles R. Kummeth sold 33,031 shares of TECH on 07/09/2019 at an average price of $212.6 a share.
About TECH
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates in two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment offers proteins and reagent solutions, including cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and T-Cell activation technologies. This segment also provid... [Read more...]
| Industry Biotechnology | IPO Date Feb 9, 1989 |
| CEO Charles Kummeth | Employees 2,300 |
| Stock Exchange NASDAQ | Ticker Symbol TECH |
Financial Performance
In 2020, Bio-Techne's revenue was $738.69 million, an increase of 3.46% compared to the previous year's $714.01 million. Earnings were $229.30 million, an increase of 138.67%.
Analyst Forecasts
According to 12 analysts, the average rating for Bio-Techne stock is "Buy." The 12-month stock price forecast is 328.56, which is a decrease of -7.86% from the latest price.